What is the current RNA Interference (RNAi)-Based Therapeutics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the RNAi-Based Therapeutics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the RNAi-Based Therapeutics market?

Increasing demand for targeted therapies and advancements in RNAi technology drive the market.

What are the major challenges facing the RNAi-Based Therapeutics market?

Delivery and stability issues, along with high development costs, pose significant challenges.

Which regions are leading the RNAi-Based Therapeutics market?

North America and Europe are currently the leading regions in the market.

Who are the top companies in the RNAi-Based Therapeutics market?

Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sanofi are among the top market players.

What future opportunities exist in the RNAi-Based Therapeutics market?

Emerging applications in oncology and genetic disorders offer significant future opportunities.

How will advances in technology impact the RNAi-Based Therapeutics market?

Advances in RNAi technology and delivery systems will improve efficacy and expand treatment options.

What is the current regulatory landscape for RNAi-Based Therapeutics?

Regulatory frameworks are evolving to support the development and approval of RNAi-Based Therapeutics.

What is the future outlook for the RNA Interference (RNAi)-Based Therapeutics market?

The market is expected to experience significant growth, driven by increasing demand and technological advancements.

RNA Interference (RNAi)-Based Therapeutics Trends, Opportunities & Forecast 2033

RNA Interference (RNAi)-Based Therapeutics by Application (AHP, hATTR, Other), by Types (siRNA, miRNA, shRNA), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12400 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12400 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

RNA Interference (RNAi)-Based Therapeutics Market Overview

The RNA Interference (RNAi)-Based Therapeutics market refers to the industry focused on developing and commercializing therapies that utilize RNA interference (RNAi) technology to treat various diseases. As a key sector within the broader biotechnology and pharmaceutical industries, the RNAi-Based Therapeutics market size is estimated to be approximately $2.2 billion in 2025. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of around 20% during the forecast period from 2026 to 2033, driven by industry expansion and increasing investments in research and development. The scope of this market encompasses various types of RNAi-based therapies, including small interfering RNA (siRNA) and microRNA (miRNA), and their applications across different disease areas such as oncology, genetic disorders, and infectious diseases.

Loading chart…

Key forces shaping the RNAi-Based Therapeutics industry include advances in gene silencing technology, evolving regulatory landscapes that support innovation, and changing consumer behavior towards personalized medicine. The largest region for this market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing investments in biotechnology research and development. As the market continues to grow, it is expected to be influenced by factors such as competitive intensity, supply-chain dynamics, and the development of new RNAi-based therapies that can address unmet medical needs.

Report Overview

Report Attribute	Details
Market size value in 2025	12.40 billion
Revenue forecast in 2033	38.20 billion
Growth rate	CAGR of 15.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals; Novartis; Sylentis; Arrowhead Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals (now part of Novo Nordisk)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The RNA Interference (RNAi)-Based Therapeutics market is poised for significant growth, driven by factors that are reshaping the industry landscape. Understanding these dynamics is crucial for stakeholders to navigate the market effectively.

Growth Drivers2 items

Advancements in RNA Interference (RNAi) technology are leading to the development of more efficient and targeted therapies, thereby driving the RNA Interference (RNAi)-Based Therapeutics market size and its growth forecast.

Increasing investments in research and development by pharmaceutical companies and biotech firms are fueling innovation in the RNA Interference (RNAi)-Based Therapeutics market.

Restraints2 items

High development costs and the lengthy regulatory approval process are significant restraints for companies looking to enter the RNA Interference (RNAi)-Based Therapeutics market.

Off-target effects and potential long-term side effects of RNA Interference (RNAi)-Based Therapeutics remain a concern, impacting their adoption rate and the overall growth forecast of the market.

Opportunities2 items

The increasing prevalence of genetic disorders and diseases creates a vast opportunity for RNA Interference (RNAi)-Based Therapeutics to offer novel treatment options, thereby expanding the RNA Interference (RNAi)-Based Therapeutics market size.

Collaborations and partnerships between pharmaceutical companies, research institutions, and biotech firms can accelerate the development and commercialization of RNA Interference (RNAi)-Based Therapeutics, enhancing the market's growth forecast.

Challenges2 items

The complexity of RNA Interference (RNAi) technology and the need for specialized expertise pose significant challenges for new entrants in the RNA Interference (RNAi)-Based Therapeutics market.

Ensuring the stability and delivery of RNA Interference (RNAi)-Based Therapeutics to the target site within the body remains a technical challenge that companies must address to achieve market success and meet the growth forecast.

Market Segmentation

Loading chart…

The Application segment of the RNA Interference (RNAi)-Based Therapeutics market is a crucial aspect of market taxonomy, as it defines the therapeutic areas where RNAi-based therapeutics are applied. This segment includes various disease categories such as genetic disorders, infectious diseases, and cancer, among others. Each application area has its unique set of challenges and opportunities, contributing to the overall RNA Interference (RNAi)-Based Therapeutics market size. Understanding the application segment is essential for stakeholders to identify potential areas of growth and development in the RNAi-based therapeutics market.

The Types segment of the RNA Interference (RNAi)-Based Therapeutics market refers to the different subtypes of RNAi-based therapeutics, including small interfering RNA (siRNA), microRNA (miRNA), and short hairpin RNA (shRNA). Each subtype has its distinct characteristics, advantages, and limitations, influencing the overall market dynamics. The Types segment is critical in RNA Interference (RNAi)-Based Therapeutics segmentation, as it enables stakeholders to analyze the competitive landscape, assess market trends, and make informed decisions about investments and product development.

RNA Interference (RNAi)-Based Therapeutics Segmentation Breakdown8 items

Application

AHP

hATTR

Other

Types

siRNA

miRNA

shRNA

Regional Insights

Loading chart…

The RNA Interference (RNAi)-Based Therapeutics market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The Asia Pacific region is expected to be the fastest-growing region, driven by increasing adoption of RNAi-based therapeutics, favorable policies, and significant investments in the healthcare sector.

Key drivers for North America include a mature ecosystem, high infrastructure spending, and a large patient population. In Europe, drivers include a strong regulatory framework, increasing demographics with age-related diseases, and growing research collaborations. Asia Pacific's growth is fueled by expanding healthcare access, rising income levels, and strategic partnerships between local and international companies.

Latin America and Middle East & Africa are also expected to contribute to the regional forecast, with key drivers including growing awareness of RNAi-based therapeutics, improving healthcare infrastructure, and increasing foreign investments. However, these regions face challenges such as limited access to healthcare and regulatory hurdles.

Competitive Landscape

The RNA Interference (RNAi)-Based Therapeutics competitive landscape is moderately consolidated, with a mix of global players and local companies competing for market share. The market is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are leveraging their scale and resources to drive innovation and expansion, while local companies are focusing on regional expertise and partnerships to stay competitive. Understanding the RNA Interference (RNAi)-Based Therapeutics key players and their strategies is crucial for navigating this complex landscape.

Companies in this market are employing various strategies to differentiate themselves and gain a competitive edge. Common strategies include M&A, partnerships, product launches, expansion, R&D, and localization. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies are focusing on technology, service model, channel strength, customization, and cost advantages to differentiate themselves. The following companies are implementing strategic focuses:

Alnylam Pharmaceuticals: innovation pipeline

Novartis: regional expansion

Sylentis: local manufacturing

Arrowhead Pharmaceuticals: vertical integration

Silence Therapeutics: premium pricing

Dicerna Pharmaceuticals: OEM tie-ups

Key RNA Interference (RNAi)-Based Therapeutics Companies6 items

Alnylam Pharmaceuticals

Novartis

Sylentis

Arrowhead Pharmaceuticals

Silence Therapeutics

Dicerna Pharmaceuticals (now part of Novo Nordisk)

Market Ecosystem

The RNA Interference (RNAi)-Based Therapeutics ecosystem spans upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured as technology providers supply critical components, which are then integrated and distributed to end users through various channels. Understanding this ecosystem is crucial for value chain analysis and identifying opportunities for growth and innovation.

Raw material suppliers — providing RNAi-related materials

Technology providers — developing RNAi-based therapies

OEMs / manufacturers — producing RNAi-based therapeutic products

System integrators / EPCs — integrating RNAi-based therapies into treatment plans

Distributors / channel partners — delivering RNAi-based therapies to end users

Regulators/standards bodies — overseeing RNAi-based therapeutic approvals and standards

End users / buyers — receiving RNAi-based therapies for treatment

The flow of value in the RNA Interference (RNAi)-Based Therapeutics ecosystem is influenced by control points, such as regulatory bodies and technology providers, which can impact adoption and growth. Dependency risks, including input constraints and standards, can also affect the ecosystem. Furthermore, switching costs and partnerships can create barriers to entry, while interoperability requirements may vary by region, leading to differences in the ecosystem's structure and dynamics across diverse areas.

Recent Industry Insights

The RNA Interference (RNAi)-Based Therapeutics industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships and collaborations have been forged, such as the alliance between Alnylam Pharmaceuticals and Regeneron Pharmaceuticals to develop RNAi-based therapies. Additionally, there have been key mergers and acquisitions, including the acquisition of Dicerna Pharmaceuticals by Novo Nordisk, further solidifying the industry's growth trajectory. Recent product launches, such as the introduction of new RNAi-based treatments for rare genetic disorders, have also contributed to the industry's expansion.

Furthermore, regulatory changes and funding rounds have played a crucial role in shaping the RNA Interference (RNAi)-Based Therapeutics industry trends. The FDA's approval of new RNAi-based therapies has paved the way for increased adoption, while significant funding rounds have enabled companies to advance their research and development efforts. As the industry continues to evolve, it is likely that we will see a shift in consumer and enterprise trends, with a growing focus on personalized medicine and targeted therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the RNA Interference (RNAi)-Based Therapeutics market outlook. The market exhibits a high level of attractiveness due to its potential in treating various diseases. The competitive intensity is moderate, with key players investing heavily in research and development. The long-term outlook is promising, driven by advancements in technology and increasing demand for targeted therapies.

The innovation landscape is rapidly evolving, with new players entering the market and existing ones expanding their portfolios. However, the demand-supply balance is a concern, with a potential shortage of skilled personnel and infrastructure. Key risk factors include regulatory challenges, high development costs, and intellectual property issues. Despite these challenges, the RNA Interference (RNAi)-Based Therapeutics market is poised for significant growth, driven by its potential to revolutionize the treatment of various diseases.

11 items

1. Executive Summary

2. RNA Interference (RNAi)-Based Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global RNA Interference (RNAi)-Based Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global RNA Interference (RNAi)-Based Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. AHP

6.1.2. hATTR

6.1.3. Other

6.2. Global RNA Interference (RNAi)-Based Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. siRNA

6.2.2. miRNA

6.2.3. shRNA

6.3. Global RNA Interference (RNAi)-Based Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global RNA Interference (RNAi)-Based Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global RNA Interference (RNAi)-Based Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global RNA Interference (RNAi)-Based Therapeutics Market Competition by Key Manufacturers

8.1. Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global RNA Interference (RNAi)-Based Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alnylam Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sylentis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Arrowhead Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Silence Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dicerna Pharmaceuticals (now part of Novo Nordisk)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global RNA Interference (RNAi)-Based Therapeutics Market

Figure 4: Global RNA Interference (RNAi)-Based Therapeutics Market: Drivers

Figure 5: Global RNA Interference (RNAi)-Based Therapeutics Market: Challenges

Figure 6: Global RNA Interference (RNAi)-Based Therapeutics Market: Trends

Figure 7: Global RNA Interference (RNAi)-Based Therapeutics Market: Opportunity

Figure 8: Global RNA Interference (RNAi)-Based Therapeutics Market: Restraint

Figure 9: Global RNA Interference (RNAi)-Based Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global RNA Interference (RNAi)-Based Therapeutics Market Value (USD Million) By Region

Figure 15: Global RNA Interference (RNAi)-Based Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global RNA Interference (RNAi)-Based Therapeutics Market Value (USD Million) By Region

Figure 23: Global RNA Interference (RNAi)-Based Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global RNA Interference (RNAi)-Based Therapeutics Market Value (USD Million) By Region

Table 10: Global RNA Interference (RNAi)-Based Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global RNA Interference (RNAi)-Based Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global RNA Interference (RNAi)-Based Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global RNA Interference (RNAi)-Based Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 31: Alnylam Pharmaceuticals. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Sylentis Basic Information And Sales Area

Table 35: Sylentis. Products Portfolio

Table 36: Arrowhead Pharmaceuticals Basic Information And Sales Area

Table 37: Arrowhead Pharmaceuticals. Products Portfolio

Table 38: Silence Therapeutics Basic Information And Sales Area

Table 39: Silence Therapeutics. Products Portfolio

Table 40: Dicerna Pharmaceuticals (now part of Novo Nordisk) Basic Information And Sales Area

Table 41: Dicerna Pharmaceuticals (now part of Novo Nordisk). Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global RNA Interference (RNAi)-Based Therapeutics Market Value (USD Million) By Region

Table 47: Global RNA Interference (RNAi)-Based Therapeutics Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

RNA Interference (RNAi)-Based Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.40 billion
Revenue forecast in 2033	38.20 billion
Growth rate	CAGR of 15.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals; Novartis; Sylentis; Arrowhead Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals (now part of Novo Nordisk)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing investments in research and development by pharmaceutical companies and biotech firms are fueling innovation in the RNA Interference (RNAi)-Based Therapeutics market.

Restraints2 items

High development costs and the lengthy regulatory approval process are significant restraints for companies looking to enter the RNA Interference (RNAi)-Based Therapeutics market.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

RNA Interference (RNAi)-Based Therapeutics Segmentation Breakdown8 items

Application

AHP

hATTR

Other

Types

siRNA

miRNA

shRNA

Regional Insights

Loading chart…

Competitive Landscape

Alnylam Pharmaceuticals: innovation pipeline

Novartis: regional expansion

Sylentis: local manufacturing

Arrowhead Pharmaceuticals: vertical integration

Silence Therapeutics: premium pricing

Dicerna Pharmaceuticals: OEM tie-ups

Key RNA Interference (RNAi)-Based Therapeutics Companies6 items

Alnylam Pharmaceuticals

Novartis

Sylentis

Arrowhead Pharmaceuticals

Silence Therapeutics

Dicerna Pharmaceuticals (now part of Novo Nordisk)

Market Ecosystem

Raw material suppliers — providing RNAi-related materials

Technology providers — developing RNAi-based therapies

OEMs / manufacturers — producing RNAi-based therapeutic products

System integrators / EPCs — integrating RNAi-based therapies into treatment plans

Distributors / channel partners — delivering RNAi-based therapies to end users

Regulators/standards bodies — overseeing RNAi-based therapeutic approvals and standards

End users / buyers — receiving RNAi-based therapies for treatment

Recent Industry Insights

Analyst Overview

Table of Contents